New COVID-19 Vaccine to Seek Emergency Use Authorization from FDA
Sanofi and GSK are expected to request Emergency Use Authorization from the United States Food and Drug Administration (FDA) for its two-dose COVID-19 vaccine that uses traditional immunization technology rather than the new mRNA approach implemented by the Pfizer and Moderna COVID-19 shots. The new vaccine regimen demonstrated 100% efficacy against severe COVID-19 illness and hospitalization and 75% effectiveness against moderate to severe disease. This option may appeal to individuals who have declined vaccination due to unease regarding the mRNA technology. Click here to read more.